Fundraise

China's Tushen Zhihe raises hundreds of millions of yuan for AI protein design

What's the deal? Tushen ZhiheDealroom has a profile for this one. Try Dealroom →, a Chinese AI protein-design startup, has raised a combined several hundred million yuan across Pre-A and Pre-A+ rounds. Shanghai STVC GroupDealroom has a profile for this one. Try Dealroom → led the Pre-A, with Zhongsheng Yinling and Zhoushan Tuyi joining; Jinding CapitalDealroom has a profile for this one. Try Dealroom →, Megarobo, and Zero2IPO Holdings backed the Pre-A+.

What's the endgame? Founded in 2023, the Wuxi-based company builds AI models to design proteins for drugs, targeting hard-to-drug targets such as GPCRs, antibodies, and cyclic peptides. Its ToursynClaw platform runs a "design—experiment—feedback—redesign" loop that pairs AI generation with automated wet-lab testing.

What's the money for? The company will push several in-house pipelines toward investigational new drug (IND) filings, upgrade ToursynClaw, and expand its AI, R&D, and commercial teams. It is also deepening ties with domestic and multinational drugmakers to pursue licensing and co-development deals.

Why now? Tushen Zhihe says it has completed real-lab validation across more than 100 antibody-engineering projects, generating over 5,000 experimental data points and running a round of wet-dry validation in 14 days. Founder and chief executive officer Wang Yuguang said the measure of AI drug design is not benchmark scores but "whether it can design molecules with real functional activity and good druggability."

What could go wrong? The disclosed validation data mark lab progress, not clinical or commercial proof. The company's ultimate value hinges on turning model outputs into advanceable drug candidates and partnership revenue — neither yet demonstrated.

The signal: The round reflects rising investor and industry appetite for AI drug discovery, where strategic backers increasingly favour teams that close the loop between AI design and real-world experiments. The presence of industrial investors like Megarobo and China Biopharmaceutical's Zhongsheng Yinling signals that validation capability, not just model performance, is becoming the key endorsement in the sector.

Read more: sohu.com

Image credit: MIPT Photostream

More top stories